Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IBI343 |
Synonyms | |
Therapy Description |
IBI343 is an antibody-drug conjugate (ADC) comprising an anti-Claudin18.2 (CLDN18.2) monoclonal antibody linked to the topoisomerase I inhibitor exatecan, which potentially induces apoptosis in tumor cells expressing CLDN18.2 and results in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3037), NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IBI343 | IBI-343|IBI 343 | CLDN18.2 Antibody 19 | IBI343 is an antibody-drug conjugate (ADC) comprising an anti-Claudin18.2 (CLDN18.2) monoclonal antibody linked to the topoisomerase I inhibitor exatecan, which potentially induces apoptosis in tumor cells expressing CLDN18.2 and results in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3037), NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05458219 | Phase I | IBI343 | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | USA | AUS | 1 |